North America Intravenous Immunoglobulin Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Others), By Application, By Country and Growth Forecast, 2022 - 2028

North America Intravenous Immunoglobulin Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Others), By Application, By Country and Growth Forecast, 2022 - 2028

The North America Intravenous Immunoglobulin Market would witness market growth of 6.3% CAGR during the forecast period (2022-2028).

The immunoglobulins in intravenous immunoglobulin (IVIG) are pooled from the plasma of a thousand or more blood donors. They typically contain over most of unmodified IgG with intact Fc-dependent effector activities and just trace quantities of immunoglobulin A (IgA) or immunoglobulin M. (IgM). The benefits of an immune globulin intramuscular injection for the preventative treatment of patients with primary immunodeficiency disorders are well documented. In individuals with antibody deficiency, IVIG has therapeutic effects that go beyond antibody restoration. The range of inflammatory and autoimmune illnesses for which IVIG is utilized has skyrocketed particularly when given intravenously. From blistering skin ailments to transplant rejection and brain problems, these disorders are diverse.

The medical infrastructure of the region is witnessing an upsurge due to bringing and implementing new and advanced medical technologies to treat complex diseases. Such advanced technologies also comprises intravenous immunoglobulin. IVIg products are provided by the Canadian Blood Services. The products are available to Canadian blood banks located within hospitals, where they are dispensed to patients as prescribed by physicians. IVIg is currently used to treat primary and secondary immunodeficiencies as replacement therapy. IVIg is also used to treat autoimmune illnesses as an immunomodulatory treatment. There are six different approved signs (substitute and immunomodulatory) among the eight IVIg products available in Canada, comprising primary and secondary immunodeficiencies (PID/SID), each with many different primary pathologies.

Despite the fact that no single medication is indicated for all of these disorders in Canada, Canadian hospitals offer a number of IVIg medicines that are frequently interchanged. Canada has the biggest per-capita consumption of IVIg products in the world, and IVIg use has been gradually expanding in Canada for the past two decades.

The US market dominated the North America Intravenous Immunoglobulin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5,422.4 million by 2028. The Canada market is experiencing a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 7.8% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Others
By Application
  • Immunodeficiency Diseases
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia & Myasthenia Gravis
  • Congenital AIDS & Multifocal Motor Neuropathy
  • Kawasaki Disease
  • Guillain-Barre Syndrome
  • Immune thrombocytopenia (ITP)
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Baxter International, Inc.
  • Biotest AG (Tiancheng International Investment Limited)
  • LFB S.A.
  • CSL Limited (CSL Behring)
  • Octapharma AG
  • Kedrion S.p.A
  • Bayer AG
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Intravenous Immunoglobulin Market, by Distribution Channel
1.4.2 North America Intravenous Immunoglobulin Market, by Application
1.4.3 North America Intravenous Immunoglobulin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Intravenous Immunoglobulin Market by Distribution Channel
3.1 North America Hospital Pharmacy Market by Country
3.2 North America Specialty Pharmacy Market by Country
3.3 North America Others Market by Country
Chapter 4. North America Intravenous Immunoglobulin Market by Application
4.1 North America Immunodeficiency Diseases Market by Country
4.2 North America Chronic Inflammatory Demyelinating Polyneuropathy Market by Country
4.3 North America Hypogammaglobulinemia Market by Country
4.4 North America Chronic Lymphocytic Leukemia & Myasthenia Gravis Market by Country
4.5 North America Congenital AIDS & Multifocal Motor Neuropathy Market by Country
4.6 North America Kawasaki Disease Market by Country
4.7 North America Guillain-Barre Syndrome Market by Country
4.8 North America Immune thrombocytopenia (ITP) Market by Country
4.9 North America Others Market by Country
Chapter 5. North America Intravenous Immunoglobulin Market by Country
5.1 US Intravenous Immunoglobulin Market
5.1.1 US Intravenous Immunoglobulin Market by Distribution Channel
5.1.2 US Intravenous Immunoglobulin Market by Application
5.2 Canada Intravenous Immunoglobulin Market
5.2.1 Canada Intravenous Immunoglobulin Market by Distribution Channel
5.2.2 Canada Intravenous Immunoglobulin Market by Application
5.3 Mexico Intravenous Immunoglobulin Market
5.3.1 Mexico Intravenous Immunoglobulin Market by Distribution Channel
5.3.2 Mexico Intravenous Immunoglobulin Market by Application
5.4 Rest of North America Intravenous Immunoglobulin Market
5.4.1 Rest of North America Intravenous Immunoglobulin Market by Distribution Channel
5.4.2 Rest of North America Intravenous Immunoglobulin Market by Application
Chapter 6. Company Profiles
6.1 Grifols, S.A
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional & Segmental Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Product Launches and Product Expansions:
6.1.5.2 Acquisition and Mergers:
6.2 Takeda Pharmaceutical Company Limited
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals and Trials:
6.3 Baxter International, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Biotest AG (Tiancheng International Investment Limited)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.5 LFB S.A.
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 CSL Limited (CSL Behring)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Octapharma AG
6.7.1 Company Overview
6.7.2 Recent strategies and developments:
6.7.2.1 Approvals and Trials:
6.8 Kedrion S.p.A
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expenses
6.9 Bayer AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings